BMY240719C42000
- 1.19
- -0.06-4.80%
Bristol-Myers Squibb Newsroom
TD Cowen Adjusts Price Target on Bristol-Myers Squibb to $45 From $67
Goldman Sachs Trims Price Target on Bristol-Myers Squibb to $55 From $56, Buy Rating Maintained
Bristol-Myers Squibb: Hold Rating Maintained Amid Growth Challenges and Uncertain Long-Term Prospects
Hold Rating on Bristol-Myers Squibb Amid Balanced Strengths and Long-Term Revenue Concerns
Morgan Stanley Sticks to Its Sell Rating for Bristol-Myers Squibb (BMY)
Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $50 From $54, Maintains Neutral Rating
Bristol-Myers Squibb Analyst Ratings
Barclays Adjusts Price Target on Bristol-Myers Squibb to $41 From $43
Bristol-Myers Squibb (BMY) Gets a Hold From Wells Fargo
Wells Fargo Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)
Analysts Offer Insights on Healthcare Companies: Lyra Therapeutics (LYRA), Bristol-Myers Squibb (BMY) and Axsome Therapeutics (AXSM)
HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating
Bristol-Myers Squibb Analyst Ratings
Truist Cuts Price Target on Bristol-Myers Squibb to $64 From $68, Keeps Buy Rating
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), Laboratory (LH) and Bristol-Myers Squibb (BMY)
Bristol-Myers Squibb: Hold Rating Amid Mixed Performance and Future Revenue Concerns
Barclays Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)
Cantor Fitzgerald Adjusts Price Target on Bristol-Myers Squibb to $45 From $52, Maintains Neutral Rating
Bristol-Myers Squibb: A Hold Rating Amid Mixed Financial Outlook and Upcoming Strategic Updates